A carregar...
Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
BACKGROUND: Vedolizumab, an anti‐α(4)β(7) integrin monoclonal antibody (mAb), is indicated for treating patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). As higher therapeutic mAb concentrations have been associated with greater efficacy in inflammato...
Na minha lista:
| Publicado no: | Aliment Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5032981/ https://ncbi.nlm.nih.gov/pubmed/25996351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13243 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|